As of Thursday close, Zymeworks Inc.’s (NASDAQ:ZYME) stock traded at $7.32. The average number of shares traded per day over the past five days has been 981,780 shares. 2 times new highs have been achieved over the past 5 days, with a $0.04 gain in that time frame. In the last twenty days, the average volume was 634,510, while in the previous 50 days, it was 715,406.
Since last month, ZYME stock retreated -14.59%. Shares of the company fell to $7.17 on 08/02/23, the lowest level in the past month. A 52-week high of $10.80 was reached on 01/19/23 after having rallying from a 52-week low of $4.11. Since the beginning of this year, ZYME’s stock price has dropped by -6.87% or -$0.54, and marked a new high 7 times. However, the stock has declined by -32.22% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ZYME stock investors should be aware that Zymeworks Inc. (ZYME) stock had its last reported insider trading activity 49 days ago on Jun 16. EcoR1 Capital, LLC, the 10% Owner of the company, purchased of 3,350,000 shares for $8.12 on Jun 16. It resulted in a $27,202,000 investment by the insider. EcoR1 Capital, LLC added 200,000 shares at an average price of $8.00 on Mar 28. The insider now owns 10,087,473 shares following the transaction. On Mar 10, President & COO Klompas Neil A sold 2,977 shares at $7.83 apiece. The transaction was valued at $23,298.
Valuation Metrics
Right now, Zymeworks Inc. (ZYME) has a P/E ratio of about 2.84. The stock’s beta is 0.93. Besides these, the trailing price-to-sales (P/S) ratio of 1.05, the price-to-book (PB) ratio of 1.03, and the price-to-cash flow ratio of 4.38 may also be considered.
Financial Health
In the three months ended March 30, Zymeworks Inc.’s quick ratio stood at 6.30, while its current ratio was 6.30, showing that the company is able to pay off its debt. In the year ended March 30, operating margins totaled 39.40%. Based on annual data, ZYME earned $203.89 million in gross profit and brought in $412.48 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 24.30%. Return on equity (ROE) for the past 12 months was 50.50%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ZYME’s revenue rose 94.6% to $402.49 million during the quarter, while net income inched up to $35.58 million. While analysts expected Zymeworks Inc. to report -$0.54 quarterly earnings, the actual figure was -$0.36 per share, beating the consensus estimate by 33.30%. During the quarter, the company generated -$24.38 million in EBITDA. The liabilities of Zymeworks Inc. were 127.2 million at the end of its most recent quarter ended March 30, and its total debt was $27.34 million.
Technical Picture
This quick technical analysis looks at Zymeworks Inc.’s (ZYME) price momentum. With a historical volatility rate of 38.52%, the RSI 9-day stood at 34.12% on 03 August.
With respect to its five-day moving average, the current Zymeworks Inc. price is up by +0.55% percent or $0.04. At present, ZYME shares trade -10.51% below its 20-day simple moving average and -7.69% percent below its 100-day simple moving average. However, the stock is currently trading approximately -20.35% below its SMA50 and +32.61% above its SMA200.
Stochastic coefficient K was 14.12% and Stochastic coefficient D was 13.40%, while ATR was 0.31. Given the Stochastic reading of 14.08% for the 14-day period, the RSI (14) reading has been calculated as 36.40%. As of today, the MACD Oscillator reading stands at -0.02, while the 14-day reading stands at -0.19.
Analyst Ratings
Zymeworks Inc. (ZYME) has been rated Overweight by analysts. According to 0 brokerage firms, ZYME is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Zymeworks Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $13.00, the current consensus forecast for the stock is $8.00 – $19.00. Based on these forecasts, analysts predict Zymeworks Inc. (ZYME) will achieve an average price target of $13.61.
